Skip to content

Study · Animal study (in vivo) · rat · 1991

12 results

Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I), IGF-II and des(1-3)IGF-I in rats.

Ballard FJ, Knowles SE, Walton PE, Edson K, Owens PC, Mohler MA, Ferraiolo BL

The Journal of endocrinology1 Feb 1991Cited by 43 (Europe PMC)

PMID2005410 (opens in a new tab)DOI10.1677/joe.0.1280197 (opens in a new tab)PepBankPUB-02005410
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In rats after intravenous tracer injection, most des(1‑3)IGF-I radioactivity remained free despite increased binding protein association.

    In plain wordsIn rats, most labelled des(1‑3)IGF-I remained free in blood after intravenous injection.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    Direction not reportedFree plasma radioactivity
    Study

    ratn: not reported in source

    Labelled IGF tracer administration
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intravenousAs given in this study (rat).

    Source sentences

    Summary
    A greater degree of binding of IGF peptides with binding proteins occurred after i.v. injection of the tracers into rats, but most of the des(1-3)IGF-I radioactivity remained free.
  2. 02AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, des(1‑3)IGF-I plasma clearance was 4.59 ml/min per kg, greater than IGF-I and IGF-II clearance.

    In plain wordsIn rats, labelled des(1‑3)IGF-I left blood faster than IGF-I and IGF-II.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseTotal plasma clearance
    Study

    ratn: not reported in source

    Labelled IGF tracer administration
    Comparator
    IGF-I and IGF-II
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intravenousAs given in this study (rat).

    Measurements

    Plasma clearance
    4.59 ml/min per kg
    des(1-3)IGF-I

    Source sentences

    Summary
    Measurement of the total plasma clearances showed the rapid removal of des(1-3)IGF-I compared with IGF-I and IGF-II; the mean clearances were 4.59, 1.20 and 1.34 ml/min per kg respectively.
  3. 03AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, des(1‑3)IGF-I steady-state distribution volume was 461 ml/kg, greater than IGF-I and IGF-II values.

    In plain wordsIn rats, labelled des(1‑3)IGF-I had a larger distribution volume than IGF-I and IGF-II.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseSteady-state distribution volume
    Study

    ratn: not reported in source

    Labelled IGF tracer administration
    Comparator
    IGF-I and IGF-II
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intravenousAs given in this study (rat).

    Measurements

    Steady-state volume of distribution
    461 ml/kg
    des(1-3)IGF-I

    Source sentences

    Summary
    The mean steady-state volume of distribution was larger for des(1-3)IGF-I than for IGF-I and IGF-II (461, 167 and 181 ml/kg respectively), probably because of the differences in plasma protein binding.
  4. 04AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, all tracers including des(1‑3)IGF-I accumulated more radioactivity in kidneys than other organs.

    In plain wordsIn rats, labelled des(1‑3)IGF-I accumulated more in kidneys than other organs.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseKidney radioactivity accumulation
    Study

    ratn: not reported in source

    Labelled IGF tracer administration
    Comparator
    Other organs
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intravenousAs given in this study (rat).

    Source sentences

    Summary
    With all tracers, radioactivity appeared in the kidneys to a greater extent than in other organs.
  5. 05AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, adrenal radioactivity was greatest with des(1‑3)IGF-I, followed by IGF-I and IGF-II.

    In plain wordsIn rats, adrenal radioactivity was higher with labelled des(1‑3)IGF-I than IGF-I and IGF-II.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseAdrenal radioactivity
    Study

    ratn: not reported in source

    Labelled IGF tracer administration
    Comparator
    IGF-I and IGF-II
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intravenousAs given in this study (rat).

    Source sentences

    Summary
    The amount of radioactivity found in the adrenals, brain, skin, stomach, duodenum, ileum plus jejunum and colon was in rank order, des(1-3)IGF-I greater than IGF-I greater than IGF-II.
  6. 06AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, brain radioactivity was greatest with des(1‑3)IGF-I, followed by IGF-I and IGF-II.

    In plain wordsIn rats, brain radioactivity was higher with labelled des(1‑3)IGF-I than IGF-I and IGF-II.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseBrain radioactivity
    Study

    ratn: not reported in source

    Labelled IGF tracer administration
    Comparator
    IGF-I and IGF-II
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intravenousAs given in this study (rat).

    Source sentences

    Summary
    The amount of radioactivity found in the adrenals, brain, skin, stomach, duodenum, ileum plus jejunum and colon was in rank order, des(1-3)IGF-I greater than IGF-I greater than IGF-II.
  7. 07AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, skin radioactivity was greatest with des(1‑3)IGF-I, followed by IGF-I and IGF-II.

    In plain wordsIn rats, skin radioactivity was higher with labelled des(1‑3)IGF-I than IGF-I and IGF-II.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseSkin radioactivity
    Study

    ratn: not reported in source

    Labelled IGF tracer administration
    Comparator
    IGF-I and IGF-II
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intravenousAs given in this study (rat).

    Source sentences

    Summary
    The amount of radioactivity found in the adrenals, brain, skin, stomach, duodenum, ileum plus jejunum and colon was in rank order, des(1-3)IGF-I greater than IGF-I greater than IGF-II.
  8. 08AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, stomach radioactivity was greatest with des(1‑3)IGF-I, followed by IGF-I and IGF-II.

    In plain wordsIn rats, stomach radioactivity was higher with labelled des(1‑3)IGF-I than IGF-I and IGF-II.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseStomach radioactivity
    Study

    ratn: not reported in source

    Labelled IGF tracer administration
    Comparator
    IGF-I and IGF-II
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intravenousAs given in this study (rat).

    Source sentences

    Summary
    The amount of radioactivity found in the adrenals, brain, skin, stomach, duodenum, ileum plus jejunum and colon was in rank order, des(1-3)IGF-I greater than IGF-I greater than IGF-II.
  9. 09AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, duodenal radioactivity was greatest with des(1‑3)IGF-I, followed by IGF-I and IGF-II.

    In plain wordsIn rats, duodenal radioactivity was higher with labelled des(1‑3)IGF-I than IGF-I and IGF-II.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseDuodenal radioactivity
    Study

    ratn: not reported in source

    Labelled IGF tracer administration
    Comparator
    IGF-I and IGF-II
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intravenousAs given in this study (rat).

    Source sentences

    Summary
    The amount of radioactivity found in the adrenals, brain, skin, stomach, duodenum, ileum plus jejunum and colon was in rank order, des(1-3)IGF-I greater than IGF-I greater than IGF-II.
  10. 10AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, ileum plus jejunum radioactivity was greatest with des(1‑3)IGF-I, followed by IGF-I and IGF-II.

    In plain wordsIn rats, ileum plus jejunum radioactivity was higher with labelled des(1‑3)IGF-I than IGF-I and IGF-II.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseIleum plus jejunum radioactivity
    Study

    ratn: not reported in source

    Labelled IGF tracer administration
    Comparator
    IGF-I and IGF-II
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intravenousAs given in this study (rat).

    Source sentences

    Summary
    The amount of radioactivity found in the adrenals, brain, skin, stomach, duodenum, ileum plus jejunum and colon was in rank order, des(1-3)IGF-I greater than IGF-I greater than IGF-II.
  11. 11AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, colon radioactivity was greatest with des(1‑3)IGF-I, followed by IGF-I and IGF-II.

    In plain wordsIn rats, colon radioactivity was higher with labelled des(1‑3)IGF-I than IGF-I and IGF-II.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseColon radioactivity
    Study

    ratn: not reported in source

    Labelled IGF tracer administration
    Comparator
    IGF-I and IGF-II
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intravenousAs given in this study (rat).

    Source sentences

    Summary
    The amount of radioactivity found in the adrenals, brain, skin, stomach, duodenum, ileum plus jejunum and colon was in rank order, des(1-3)IGF-I greater than IGF-I greater than IGF-II.
  12. 12LabIn vitro (cell-free)Activity measurement

    In rat plasma incubations, labelled des(1‑3)IGF-I showed essentially absent association with binding protein complexes.

    In plain wordsIn lab tests with rat plasma, labelled des(1‑3)IGF-I showed almost no association with binding protein complexes.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    Not applicablePlasma binding protein association in vitro
    Study

    ratn: not reported in source

    Rat plasma incubation at 4 degrees C
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The extent of association was greater with labelled IGF-II and essentially absent with the truncated IGF-I analogue, des(1-3)IGF-I.
    1 context sentence
    Summary · context
    Incubation of 125I-labelled insulin-like growth factor-I (IGF-I) with rat plasma at 4 degrees C led to the transfer of approximately half the radioactivity to 150 kDa and smaller complexes with IGF-binding proteins.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:52 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.